Compare LyondellBasell Industries NV (LYB) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Philip Morris International Inc. — how do they compare? LyondellBasell Industries NV trades at $60.34 (market cap $18.89B), while Philip Morris International Inc. trades at $199.83 (market cap $300.33B). The key difference: Philip Morris International Inc. is far larger — about 15.9× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 87 Days and Philip Morris International Inc. for 85 Days on average.
| LYB | PM | |
|---|---|---|
Market Cap | $18.89B | $300.33B |
Volume | 2,621,859 | 3,935,700 |
Sector | Basic Materials | Consumer Staples |
52-Week High | $82.38 | $200.50 |
52-Week Low | $42.28 | $144.33 |
Typical Hold Time | 87 Days | 85 Days |
Enterprise Value | $30.48B | $343.44B |
Dividend Yield | 4.72% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $60.36, up 2.42% today, with a bearish technical signal but mixed fundamental outlook. Revenue declined to $30.15B in 2025, resulting in a net loss of $745M, though recent quarters show earnings beats. The stock is supported by a 45% analyst buy rating and a $69.38 consensus price target, but faces headwinds from cyclical chemical demand and high debt levels.
LYB offers potential upside from operational recovery and dividend yield, but risks include volatile earnings, margin pressure, and industry competition. The stock remains a speculative play on chemical sector stabilization, with investor sentiment divided between near-term challenges and long-term value.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
